ReviewClinics in liver disease2016
Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities.
Review in Clinics in liver disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Biology of the hepatitis B virus (HBV) core and capsid assembly modulators (CAMs) for chronic hepatitis B (CHB) cure.Global health & medicine · 2023Review
- Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus.Clinical and molecular hepatology · 2022Review
- Article
- Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral ResponsesAntimicrobial agents and chemotherapy · 2020Article
- Pharmacological plasticity-How do you hit a moving target?Pharmacology research & perspectives · 2019Review
- 2019 meeting of the global virus network.Antiviral research · 2019Review
- Article
- Prevalence and genetic diversity of HCV among HIV-1 infected individuals living in Ahvaz, Iran.BMC infectious diseases · 2019Article
- 5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors.European journal of medicinal chemistry · 2019Article
- Divergent synthesis of a thiolate-based α-hydroxytropolone library with a dynamic bioactivity profile.RSC advances · 2019Article
- Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study.Antiviral therapy · 2019Article
- Ideal Cure for Hepatitis B Infection: The Target is in Sight.Journal of clinical and experimental hepatology · 2018Review
- Towards HBV curative therapies.Liver international : official journal of the International Association for the Study of the Liver · 2018Review
- Effect of modified Xiaochaihu decoction‑containing serum on HepG2.2.15 cells via the JAK2/STAT3 signaling pathway.Molecular medicine reports · 2017Article
- Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector.European journal of medicinal chemistry · 2017Article
- Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics.Molecular therapy. Nucleic acids · 2017Review
- Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.Bioorganic & medicinal chemistry letters · 2017Article
- Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues.PloS one · 2017Article
- From HCV To HBV Cure.Liver international : official journal of the International Association for the Study of the Liver · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Hepatitis B virus (HBV) causes significant morbidity and mortality worldwide. The majority of chronically infected individuals do not achieve a functional and complete cure. Treated persons who achieve a long-term sustained virologic response (undetectable HBV DNA), are still at high risk of developing morbidity and mortality from liver complications. This review focuses on novel, mechanistically diverse anti-HBV therapeutic strategies currently in development or in clinical evaluation, and highlights new combination strategies that may contribute to full elimination of HBV DNA and covalently closed circular DNA from the infected liver, leading to a complete cure of chronic hepatitis B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.